InterMune (ITMN) Reports Smaller-Than-Expected Loss; Guides In-line
More News related to ITMN
- Intermune (ITMN) March volatility at 220 on active volume into FDA meeting
- Active equity option families in first 30 minutes of trading: AAPL, C, ITMN, AMZN
- InterMune to Participate in Pulmonary-Allergy Drugs Advisory Committee Meeting on March 9, 2010
- Intermune (ITMN) March volatility at 66, April at 144 into meeting
- InterMune (ITMN) Prices 7M Common Offering at $14.10/Share
More News related to Earnings
- Baidu (BIDU) Blows the Lid Off Q4, Shares Jump
- Aspen Insurance (AHL) Posts Q4 adj.-EPS of $1.44, Tops Views
- Acadia Realty Trust (AKR) Misses Q4 FFO by 1c; Guides Below for FY10
- RenaissanceRe (RNR) Tops Q4 Views
- Taubman Centers (TCO) Reports Q4 FFO of $0.56; Guides FY10
InterMune Inc (NASDAQ: ITMN) reports a Q3 loss of $0.19, 2 cents better than the analyst estimate of ($0.21). Revenue for the quarter was $23.3 million, which compares to the estimate of $26.70 million.
Revenue: 2009 revenue, including Actimmune® and milestone payments from Roche, is expected to be in a range of approximately $45 to $50 million. Actimmune revenue represents approximately 50 percent of this revenue range. (Consensus is $48.02 million)
Related Categories
EarningsGuidance
Stocks Mentioned
+0.10Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
